CDMO

WuXi Biologics secured three awards at the Asia Pacific Biologics CDMO Excellence Awards (APBCEA) 2025, including “CDMO of the Year – Asia Pacific.” The awards recognize WuXi Biologics’ excellence in biomanufacturing, R&D, technological innovations, and partnerships. The company’s integrated platform streamlines biologics development, achieving a 6-month DNA-to-IND timeline for monoclonal antibodies. With a 100% PLI success rate and multiple regulatory inspections, WuXi Biologics offers end-to-end solutions to over 1000 clients globally. CEO Dr. Chris Chen attributes the success to the company’s commitment to quality and innovation.